Hunter Gillies - 21 Apr 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
21 Apr 2023
Net transactions value
-$71,040
Form type
4
Filing time
25 Apr 2023, 18:00:08 UTC
Previous filing
08 Feb 2023
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $6,960 +4,000 +204% $1.74* 5,960 21 Apr 2023 Direct F1
transaction AVTE Common Stock Sale $78,000 -4,000 -67% $19.50 1,960 21 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -4,000 -17% $0.000000 20,108 21 Apr 2023 Common Stock 4,000 $1.74 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
F2 A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.